mercaptopurine and Carcinoma--Papillary

mercaptopurine has been researched along with Carcinoma--Papillary* in 2 studies

Other Studies

2 other study(ies) available for mercaptopurine and Carcinoma--Papillary

Article	Year
Thyroid involvement with Langerhans cell histiocytosis in a 3-year-old male. Pediatric blood & cancer, 2008, Volume: 50, Issue:3 We report on the thyroid involvement with Langerhans cell histiocytosis (LCH) in a 3-year-old male. The patient presented with goiter and primary hypothyroidism. His goiter caused life-threatening airway obstruction. He developed locally invasive disease 4 years after his response to LCH therapy. LCH should be suspected as a cause of goiter and thyroidectomy is recommended. Topics: Airway Obstruction; Carcinoma, Papillary; Child, Preschool; Combined Modality Therapy; Goiter; Histiocytosis, Langerhans-Cell; Humans; Hypothyroidism; Male; Mercaptopurine; Methotrexate; Prednisone; Thyroid Diseases; Thyroid Neoplasms; Thyroidectomy; Thyroiditis, Autoimmune	2008
Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide. Teratogenesis, carcinogenesis, and mutagenesis, 1993, Volume: 13, Issue:3 A 29-year-old pregnant woman diagnosed with acute lymphocytic leukemia maintained remission with daily cyclophosphamide and intermittent prednisone treatment. She delivered a male twin with multiple congenital abnormalities who was diagnosed with papillary thyroid cancer at 11 years of age and stage III neuroblastoma at 14 years of age. The female twin was unaffected and has exhibited normal development to date. First trimester exposure to cyclophosphamide has been associated with major malformations. Metabolites of cyclophosphamide have been demonstrated to be teratogens and carcinogens in animals. Differences in placental or fetal hepatic cytochrome P-450 may account for the variability in response between the twins. In addition, disparity between the twins may be the result of differences in metabolite inactivating enzymes present either in fetal liver or placenta. The risk of second malignancies caused by alkylating agents such as cyclophosphamide has been well documented in adults and children but to the best of our knowledge this is the first description of transplacental second cancer. Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adrenal Gland Neoplasms; Adult; Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Cyclophosphamide; Diseases in Twins; Female; Humans; Infant, Newborn; Male; Maternal-Fetal Exchange; Mercaptopurine; Neuroblastoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pregnancy; Pregnancy Complications, Neoplastic; Prenatal Exposure Delayed Effects; Thyroid Neoplasms; Time Factors; Twins, Dizygotic; Vincristine	1993

Article

Year

Thyroid involvement with Langerhans cell histiocytosis in a 3-year-old male.

Pediatric blood & cancer, 2008, Volume: 50, Issue:3

We report on the thyroid involvement with Langerhans cell histiocytosis (LCH) in a 3-year-old male. The patient presented with goiter and primary hypothyroidism. His goiter caused life-threatening airway obstruction. He developed locally invasive disease 4 years after his response to LCH therapy. LCH should be suspected as a cause of goiter and thyroidectomy is recommended.

Topics: Airway Obstruction; Carcinoma, Papillary; Child, Preschool; Combined Modality Therapy; Goiter; Histiocytosis, Langerhans-Cell; Humans; Hypothyroidism; Male; Mercaptopurine; Methotrexate; Prednisone; Thyroid Diseases; Thyroid Neoplasms; Thyroidectomy; Thyroiditis, Autoimmune

2008

Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide.

Teratogenesis, carcinogenesis, and mutagenesis, 1993, Volume: 13, Issue:3

A 29-year-old pregnant woman diagnosed with acute lymphocytic leukemia maintained remission with daily cyclophosphamide and intermittent prednisone treatment. She delivered a male twin with multiple congenital abnormalities who was diagnosed with papillary thyroid cancer at 11 years of age and stage III neuroblastoma at 14 years of age. The female twin was unaffected and has exhibited normal development to date. First trimester exposure to cyclophosphamide has been associated with major malformations. Metabolites of cyclophosphamide have been demonstrated to be teratogens and carcinogens in animals. Differences in placental or fetal hepatic cytochrome P-450 may account for the variability in response between the twins. In addition, disparity between the twins may be the result of differences in metabolite inactivating enzymes present either in fetal liver or placenta. The risk of second malignancies caused by alkylating agents such as cyclophosphamide has been well documented in adults and children but to the best of our knowledge this is the first description of transplacental second cancer.

Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adrenal Gland Neoplasms; Adult; Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Cyclophosphamide; Diseases in Twins; Female; Humans; Infant, Newborn; Male; Maternal-Fetal Exchange; Mercaptopurine; Neuroblastoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pregnancy; Pregnancy Complications, Neoplastic; Prenatal Exposure Delayed Effects; Thyroid Neoplasms; Time Factors; Twins, Dizygotic; Vincristine

1993